menu
    • menu
    [{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"Avet Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avet Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avet Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avet Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Propofol

    Menu

    Propofol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Avenacy

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Avenacy

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Avenacy Announces Launch of Propofol Injectable Emulsion, USP in the U.S. Market

    Details : Diprivan-Generic (propofol) is an intravenous general anesthetic and sedation drug indicated for induction of general anesthesia.

    Product Name : Diprivan-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 07, 2025

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Amneal Pharmaceuticals

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Amneal Pharmaceuticals

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Amneal Receives U.S. FDA Approval For Propofol Injectable Emulsion Single Dose Vials

    Details : Diprivan-Generic (propofol) is approved in the US, which is an intravenous drug commonly used in hospitals for the induction and maintenance of anesthesia and sedation.

    Product Name : Diprivan-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 20, 2024

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Hospira, Inc.

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Hospira, Inc.

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion (containing benzyl al...

    Details : Propofol is an intravenous general anesthetic and sedation drug for use in the induction and maintenance of anesthesia or sedation. Propofol Injectable Emulsion is a terminally sterilized (TS) product.

    Product Name : Propofol-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 22, 2022

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Hospira, Inc.

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Hospira, Inc.

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion, USP (Containing Benz...

    Details : Propofol is an intravenous general anesthetic and sedation drug for use in the induction and maintenance of anesthesia or sedation. Propofol Injectable Emulsion, USP is a terminally sterilized (TS) product.

    Product Name : Propofol-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 13, 2022

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Avet Pharmaceuticals

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Avet Pharmaceuticals

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Avet Pharmaceuticals Announces Approval and Launch of Propofol Injectable Emulsion, USP

    Details : Propofol injectable emulsion, an AB-rated generic equivalent of DIPRIVAN® (propofol) Injectable Emulsion USP is an intravenous general anesthetic and sedation drug indicated for initiation and maintenance of Monitored Anesthesia Care (MAC) sedation.

    Product Name : Propofol-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 04, 2022

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Fresenius Kabi AG

    Germany arrow
    Pharma Live Expo
    Not Confirmed

    Fresenius Kabi AG

    Germany arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Premier

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential...

    Details : Premier through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.

    Product Name : Diprivan

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    July 13, 2020

    Lead Product(s) : Propofol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Premier

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth